⟵ Back to Search Results
BGB-A317-209

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Beigene Study ID info

BGB-A317-209

ClinicalTrials.gov ID info

NCT03736889

Clinical Drug Trials ID info

CTR20180867

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents